Centocor Inc. (CNTO)
Joyce Lonergan of Cowen & Co. said she wasn't surprised that the interim look at CNTO's CAPTURE trial of ReoPro in unstable angina didn't show sufficient efficacy to stop the study ahead of schedule (see BioCentury Extra May 23). Investors shouldn't draw any negative inference regarding the ultimate success of ReoPro in this indication, she said, because the drug would have to be working much better than the trial's designers had anticipated in order for the study to be stopped at this point.